Median Progression Free Survival (PFS) Up to 36 months [clinicaltrials_resource:9c9ba380f08c0547b0d3c49f2d8e1135]
Progression Free Survival is defined as the interval between the date of the first cetuximab administration and the date of objective progression of disease. Progression was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Median Progression Free Survival (PFS) Up to 36 months [clinicaltrials_resource:9c9ba380f08c0547b0d3c49f2d8e1135]
Progression Free Survival is defined as the interval between the date of the first cetuximab administration and the date of objective progression of disease. Progression was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Bio2RDF identifier
9c9ba380f08c0547b0d3c49f2d8e1135
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9c9ba380f08c0547b0d3c49f2d8e1135
measure [clinicaltrials_vocabulary:measure]
Median Progression Free Survival (PFS)
time frame [clinicaltrials_vocabulary:time-frame]
Up to 36 months
description
Progression Free Survival is d ...... f existing non-target lesions.
identifier
clinicaltrials_resource:9c9ba380f08c0547b0d3c49f2d8e1135
title
Median Progression Free Survival (PFS) Up to 36 months
@en
type
label
Median Progression Free Surviv ...... ba380f08c0547b0d3c49f2d8e1135]
@en